The boss of AstraZeneca has said that unless the UK ramps up spending on new drugs, it could be on a trajectory to only being able to afford cheap, generic medicines rather than cutting-edge treatments.
Pascal Soriot made the remarks amid an acrimonious standoff between the pharmaceutical industry and the government over drug pricing, which has been blamed for drugmakers pausing or ditching nearly £2bn of investments in the UK this year.